Drugs / pdFVII
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02470871 | Jul 2015 → Jul 2016 | congenital factor VII deficiency | CSL Behring | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pdFVII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02470871 ↗ |
| Known as | Plasma-derived FVII | “Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study.” NCT02470871 ↗ |
| Modality | Protein / enzyme biologic | “Plasma-derived FVII (pdFVII)” NCT02470871 ↗ |
| Route | Other | “single injection of pdFVII” NCT02470871 ↗ |